Pfizer agrees to drop breast and colon health claims on Centrum supplements

By Elaine Watson

- Last updated on GMT

Pfizer agrees to drop selected claims on Centrum supplements
Pfizer has agreed remove claims about breast and colon health on ads and labels for its top-selling Centrum multivitamins as part of a deal with health advocacy group the Center for Science in the Public Interest (CSPI).

As a result, the CSPI will not now take legal action against the healthcare giant, said the CSPI, which had threatened to sue if Pfizer did not amend its claims.

Centrum Ultra Women’s and Centrum Silver Women’s multivitamin supplements are claimed to support breast health, while Centrum Ultra Men’s and Centrum Silver Ultra Men’s are claimed to support colon health.

But such claims imply that the supplements might prevent breast and colon cancer, and are in effect unauthorized disease prevention claims, argued CSPI litigation director Steve Gardner.

“Supplement manufacturers must not mislead consumers into thinking that these pills will help ward off cancer.”  

Pfizer: Happy to work collaboratively with CSPI to resolve matter

In a letter to the CSPI from law firm Patton Boggs on behalf of Pfizer, Stuart Pape, a partner at Patton Boggs, rejected Gardner's analysis: “As you know from our discussions, Pfizer denies CSPI’s allegations and the changes Pfizer has agreed to make do not constitute an admission.”

However, Pfizer was happy to “work collaboratively with CSPI to resolve this matter​” and agreed to discontinue the breast and colon health claims, said Cape.

It has also agreed that Centrum supplements bearing heart health claims will include wording clarifying that they are “not a replacement for cholesterol-lowering drugs​”, he said.

Meanwhile, supplements bearing an energy claim will in future include language clarifying that they do not directly provide an energy boost, but rather help support metabolic function, he added.

Pfizer has agreed to amend its web sites and ads by early August and to amend product labels over the next six months.

CSPI: 'Pleased with the collaborative spirit with which Pfizer was willing to discuss our concerns’

“Although Pfizer disagrees with our position, we are pleased with the collaborative spirit with which Pfizer was willing to discuss our concerns and resolve them without resorting to litigation”, ​said Gardner.

Pfizer Consumer Healthcare is among the largest over-the-counter health care companies in the world with a global footprint in more than 90 countries.

The CSPI is a nonprofit health advocacy group based in Washington DC.

Related news

Show more

Related products

show more

Setting Specifications – Don’t Forget To Do This!

Setting Specifications – Don’t Forget To Do This!

Gemini Pharmaceuticals | 12-Feb-2018 | Technical / White Paper

While the regulations require Brand Owners to establish specifications for all raw materials and for the finished product, based on the number of FDA Warning...

Feeling low T-levels?

Feeling low T-levels?

Chemical Resources (CHERESO) | 12-Feb-2018 | Application Note

Healthy testosterone levels influence a broad range of men’s health goals, from maintaining healthy sexual function to supporting optimal athletic performance.

SelenoForce®: Micro-Nutrient with Macro-Potential

SelenoForce®: Micro-Nutrient with Macro-Potential

Sabinsa Corporation | 29-Jan-2018 | Data Sheet

A safe and bioavailable source of supplemental selenium, this selenium-enriched garlic product is manufactured by a patented soil-less culture technique,...

Today’s Weight Management Consumer

Today’s Weight Management Consumer

Kemin Human Nutrition & Health | 18-Jan-2018 | Infographic

The weight management market has an estimated value of $34 billion. As the percentage of overweight and obese consumers continues to rise globally, there...

Related suppliers

Follow us

Products

View more

Webinars